Last reviewed · How we verify
Metformin + Intermittent Insulin Therapy
Metformin reduces hepatic glucose production and improves insulin sensitivity, while intermittent insulin therapy provides periodic exogenous insulin to maintain glycemic control.
Metformin reduces hepatic glucose production and improves insulin sensitivity, while intermittent insulin therapy provides periodic exogenous insulin to maintain glycemic control. Used for Type 2 diabetes mellitus (Phase 3 investigational combination regimen).
At a glance
| Generic name | Metformin + Intermittent Insulin Therapy |
|---|---|
| Also known as | metformin,, basal insulin glargine and pre-meal insulin lispro |
| Sponsor | Mount Sinai Hospital, Canada |
| Drug class | Antidiabetic combination therapy |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Metformin is a biguanide that decreases gluconeogenesis and enhances peripheral glucose uptake, reducing fasting and postprandial glucose levels. Intermittent insulin therapy involves periodic insulin administration to supplement endogenous insulin secretion and achieve target blood glucose levels. The combination leverages metformin's insulin-sensitizing effects with insulin's direct glucose-lowering action.
Approved indications
- Type 2 diabetes mellitus (Phase 3 investigational combination regimen)
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (metformin)
- Weight gain (insulin)
- Injection site reactions
Key clinical trials
- Intermittent Fasting Diet Versus Resistive Exercise Program on Insulin Resistance in Obese Women With P.C.O.S (NA)
- Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease (PHASE4)
- Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial) (PHASE3)
- Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study) (PHASE3)
- The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: